For example, while SGLT2 inhibitors have emerged as a key disease-modifying therapy to reduce proteinuria and delay CKD progression [62,63], only one study assessed SGLT2 inhibitors, which were used in less than 12% of the study population [36]. This evidence concerns the gene SLC5A2 and chronic kidney disease.